How much do we know about adherence to biometric monitoring technologies (BioMeTs) in clinical trials?
- Koneksa Health
- May 11, 2022
- 1 min read
Updated: Jul 19
What did they find? As a result, the authors recommended that sensor-based, non-surrogate, quantitative adherence data should be reported for all BioMeTs. What does that mean in practice?Why does that matter?In short: the more precise your definitions are, the more your data will be able to tell you. Who did this study? Want to learn more?
I was diagnosed with Parkinson’s disease four years ago. For over two years, I relied on prescription medications and therapies, but unfortunately, the symptoms continued to worsen. My mobility declined, tremors increased, and I experienced growing fatigue and discomfort that affected my daily life. Last year, out of desperation and hope, I decided to try an herbal treatment program from NaturePath Herbal Clinic. Honestly, I was skeptical at first, but within a few months of starting the treatment, I began to notice real changes. My energy improved, the discomfort eased, and I felt stronger and more capable in my daily life. Incredibly, I also regained much of my stamina, balance, and confidence. It’s been a life-changing experience I feel more…